Replies to post #26023 on CytoSorbents Corporation (CTSO)

[Greenaccountingbean]

$CYDY leronlimab ph3 study in patients w/ severe Covid19 failed its primary endpoint - improvement in mortality. As with its previous failed study in moderate Covid, the company is spinning the data to cushion the blow of a negative outcome. https://t.co/pdxrnNby3n

— Adam Feuerstein ✡️ (@adamfeuerstein) March 5, 2021